Word: fda
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
Three years later, Dean Ebert appeared before an FDA Advisory panel which was holding a hearing on Squibb's Mysteclin-F, a drug which had been severely criticized by a National Academy of Sciences-National Research Council panel of thirty specialists on infections diseases. Critics argued that prescription of Mysteclin-F's fixed combination of several antibiotics was irrational since it tended to give the patient too much or too little of each of the antibiotics, rather than the precise dosage needed...
...story in The Washington Post raised a few eyebrows in the medical and academic communities this week. Morton Mintz, in the November 23 edition of The Post, revealed that Robert H. Ebert, dean of the Medical School, had testified before an FDA committee in his capacity as a consultant for Squibb Beechnut...
Ebert and Lewis Thomas, dean of the Yale Medical School, both testified October 13 before the FDA in defense of Mysteclin-F, a fixed combination anti-infection drug manufactured by the pharmaceutical division of Squibb...
...spite of Ebert's pro-Mysteclin testimony, the FDA decided to prohibit the sale of the commonly prescribed drug. The FDA had nearly withdrawn the drug in 1969 after a National Academy of Sciences. National Research Council panel declared Mysteclin-F to be ineffective...
Drug manufacturers are increasingly unhappy about the FDA approach. With more than 300,000 practicing physicians in the country, the cost of a letter to each can easily exceed $40,000. A two-page spread in the A.M.A. Journal alone can set a company back a minimum of $5,000. So far, however, no company has refused an FDA request for recantation. Nor is one likely to, for the alternative could be even more expensive. The law gives the FDA the authority-upheld in five cases-to seize any drug that it deems mislabeled...